Future Pharma’s Post

Mark Bard and William Veltre discussed the evolving landscape of digital trends and data-driven strategies within the pharmaceutical industry. Veltre emphasized the importance of unlocking the potential of data and utilizing it to drive brand success through attribution and collaboration across various touchpoints. They also explored the transition from traditional to digital mindsets in marketing and the significance of partnerships between agencies and pharmaceutical companies in delivering purposeful and meaningful interactions with healthcare professionals. Looking ahead, they highlighted the necessity for agility, innovation, and a deep understanding of evolving customer expectations to drive business impact in the rapidly changing healthcare landscape. https://lnkd.in/dMJc6r4V

What’s key to driving commercial success in the pharmaceutical and biotechnology industries today? 🤔 Three things: ✔️ Delivering engaging digital experiences for healthcare professionals (HCPs) across channels ✔️ Building websites and HCP portals to drive engagement ✔️ Creating personalized digital content at scale – while staying compliant. So how do you achieve this? Well, in our brand-new white paper, you’ll learn exactly that 👉 https://brnw.ch/21wGGdZ #magnoliacms #magnoliadxp #dxp #digitalengagement #biopharma #lifesciences

We're gearing up for Reuters Events: Pharma & Patient USA 2024 in Boston (Oct 15-16) and we're excited to share some thought-provoking discussions from Pharma USA. Here's a sneak peek at what you can learn >> https://bit.ly/3Lb6dX2 💊 Boost adherence, increase trial participation, and create exceptional outcomes by integrating patient perspectives from the outset. 🔍 Hear from Voters for Cures and PhRMA on the patient's perspective on biopharmaceutical innovation and the policies needed for a robust pipeline of new treatments. 🔹 Oracle shares tips on reducing trial burdens, enhancing participant recruitment/retention, and using AI for automated drug safety monitoring. 🌍 Novartis explores why health equity is a game-changer for improving outcomes in innovation, access, and patient care. 🤝 Ipsen, Nestlé Health Science, Ocugen, and Essence Patient Solutions discuss leveraging partnerships to foster a patient-first pharma culture. Join us in the journey towards a patient-centric future! #REPatientUSA #PatientCentricity #HealthcareInnovation

The world of #Pharma #marketing is rapidly transforming and what worked a few years ago might no longer be the best growth strategy today. 📉 With the rise of digital marketing channels and a decline of face-to-face access of Pharma to HCPs, the way physicians are consuming information has drastically evolved. 🔑 So, understanding the individual marketing preferences of physicians is key.   At PharmaForceIQ, our mission is to make marketing in the pharmaceutical industry more efficient through our state-of-the-art dashboard. FIND OUT MORE: https://lnkd.in/e_qgWqmZ

Pharma brands invest heavily in marketing their products to HCPs and patients. However, they often rely on anecdotal evidence about what messages most motivate different segments. Here's an exclusive report driven by the largest-ever meta-analysis of 16000+ pharma messaging in 75+ market research studies. 📌 Learn what kinds of messages perform best with HCPs and patients. 📌 Separate messaging myths vs. reality and make data-driven decisions on messaging. 📌 Explores various messaging hypotheses, like the impact of data, message length, brand name inclusion, and more. Click below to learn more! #hcp #pharmamarketing #pharmaceuticals

💡 New Development: Introducing a new way of analysing Pharma’s expenditure. At Commercial Eyes Pty Ltd, we pride ourselves on being at the forefront of innovation within the pharmaceutical and healthcare ecosystem. That is why we are so proud of our recent Competitive Intelligence initiative: a groundbreaking addition to our suite of analytical tools, designed to totally transform the way insights are extracted from transparency reports.   The recent Medicines Australia disclosure shed light on payments and transfers of value to healthcare professionals, with a reported total expenditure of $12,195,799 spent across 30 MA company members, with Novartis, Pfizer, and AstraZeneca spending the most.   To address the pressing need for more sophisticated analysis of these disclosures, our Access, Research, and Intelligence (ARI) team is launching a new, cutting-edge database next week.   By integrating multiple datasets, we unlock unprecedented depths of understanding, enabling the industry to gain competitive insights into pharmaceutical company spending patterns on individual HCPs in specific therapeutic areas.   This innovative tool is not merely an addition to existing transparency reports; it is a new framework and method to synthesise and interpret massive volumes of data.   This initiative is a testament to our commitment to driving progress and enhancing transparency within the industry. It reaffirms our position as pioneers in developing tools and frameworks that add significant value to the healthcare ecosystem.   We invite industry professionals who are seeking to understand competitor investment in particular therapeutic areas and competitor targeting of key stakeholders to discover the transformative potential of this new database.   To delve deeper into its capabilities or to engage with our Certified Intelligence Experts, please register your interest or leave a comment below. Stay tuned for more updates!   https://lnkd.in/gtAVc3-b   #Pharmaceuticals #Transparency #DataAnalytics #MedicinesAustralia #CommercialEyes #ProductLifeGroup

Great report from Deloitte giving an overview of a decade on IIR and how pharma could get more out of their R&D. At Technobis Group (Technobis Crystallization Systems) we have as our mission “help research succeeds in bringing medicines faster to patients” and with our new #ReactALL technology, developed with a team of scientists from Pfizer we show an increasing R&D effectiveness and quality of experimentation by 40% and minimizing the expensive API. Interested? https://lnkd.in/e8N54JRM

How can pharma leaders improve their R&D productivity for clinical trials and utilise #AI and technological innovations? Gain key insights from experts in this webinar on 7 May, 18:30 CET time.

"Engagement" is a well-known term in marketing, and within the pharmaceutical industry, it assumes a particular form known as HCP (Healthcare Professional) engagement. While you may frequently encounter and use this term, it's crucial to recognize that traditional engagement strategies have become outdated. As the world evolves, so do the methods for capturing the attention of your target audience. Striking the perfect balance is a significant challenge. Many pharmaceutical companies and agencies face substantial obstacles that prevent them from reaching as many potential patients and healthcare professionals (HCPs) as possible. In this post, we will explore the concept of HCP engagement in depth ⬇️ For additional insights, be sure to check the comment section for bonus material created by Viseven CEO Nataliya Andreychuk, featured on pharmaphorum!

Highlighting a Recent International Medical Conference " Key Takeaways from Global Pharma Conference 2024: We've just returned from one of the most insightful gatherings in the pharmaceutical industry, and we're eager to share our learnings with you. From the latest advancements in drug development to emerging trends in digital marketing, this conference was a goldmine of information. One key insight? The growing importance of personalized patient communication. At Proadwise, we specialize in creating targeted content that speaks directly to diverse audiences. Want to know more about the future of pharma marketing? Drop us a message!   #PharmaTrends #GlobalConferenceInsights"